PB1120
/ PhaseBio Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 20, 2018
PRE-CLINICAL EVALUATION OF VIP-ELASTINLIKE POLYPEPTIDES PB1046 AND PB1120 FOR THE TREATMENT OF CYSTIC FIBROSIS
(NACFC 2018)
- "Moreover, the molecules enhanced the effect of ivacaftor + lumacaftor. In vitro models indicate that combining PB1120 or PB1046 with ivacaftor and lumacaftor produces an additive positive effect on F508del-CFTR function and in vivo studies further demonstrate the benefit of a VIP-ELP treatment at the tissue level. Acknowledgment: Support by PhaseBio Pharmaceuticals Inc. "
Biosimilar • Cardiovascular • Cystic Fibrosis • Fibrosis • Heart Failure • Hypertension • Immunology
1 to 1
Of
1
Go to page
1